Review article: Vaccination and viral hepatitis - Current status and future prospects

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 10, 2007, Pages 1285-1292

  Koff, R S ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HEPATITIS D VACCINE; HEPATITIS VACCINE; LAMIVUDINE; PEGINTERFERON; RECOMBINANT HEPATITIS E VACCINE; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; CLINICAL TRIAL; DELTA AGENT HEPATITIS; DRUG APPROVAL; DRUG EFFICACY; HEALTH CARE PERSONNEL; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HUMAN; IMMUNIZATION; MEDLINE; NONHUMAN; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS HEPATITIS; VIRUS TRANSMISSION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS, VIRAL, HUMAN; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MALE; UNITED STATES; VACCINATION; VIRAL HEPATITIS VACCINES;

EID: 35748983797     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03517.x     Document Type: Review

References (46)

1. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 45 : 529 538.
2. CDC. Surveillance for acute viral hepatitis - United States, 2005. MMWR 2007 56 : SS 3.
3. Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006 28 : 101 111.
4. Taylor RM, Davern T, Munoz S, et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology 2006 44 : 1589 1597.
5. Koff RS. Fulminant hepatitis A: disappearing, but not soon enough. Hepatology 2006 44 : 1397 1399.
6. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004 19 : 715 727.
7. Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat 2005 12 : 101.
8. CDC. Hepatitis A vaccination coverage among children aged 24-35 months - United States, 2004 - 2005. MMWR 2007 56 : 678 681.
9. CDC. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006 55 : RR-07.
10. Van Effelterre TP, Zink TK, Hoet BJ, et al. A mathematical model of hepatitis A transmission in the United States indicates value of universal childhood immunization. Clin Infect Dis 2006 43 : 158 646.
11. Rein DB, Hicks KA, Wirth KE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 2007 119 : e12 e21.
12. Armstrong GL, Billah K, Rein DB, et al. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics 2006 119 : e22 e29.
13. Bell BP, Negus S, Fiore AE, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 2007 26 : 116 122.
14. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005 294 : 194 201.
15. Bonanni P, Franzin A, Staderini C, et al. Vaccination against hepatitis A during outbreaks starting in schools: what can we learn from experiences in central Italy? Vaccine 2005 23 : 2176 2180.
16. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007 5 : 79 84.
17. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007 356 : 895 903.
18. Andrews J. Vulnerable subjects, coercible collaboration, and the hepatitis E vaccine trial in Nepal. Persp Biol Med 2006 49 : 35 51.
19. Krawczynski K. Hepatitis E vaccine - ready for prime time. N Engl J Med 2007 356 : 949 951.
20. Dong C, Dai X, Meng JH. The first experimental study on a candidate combined vaccine against hepatitis A and E. Vaccine 2007 25 : 1662 1668.
21. CDC. Hepatitis B vaccine: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991 40 : RR-13.
22. Elefsiniotis IS, Vezali E, Kamposioras K, et al. Immunogenicity of recombinant hepatitis B vaccine in treatment-naïve and treatment- experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment. World J Gastroenterol 2006 12 : 4420 4424.
23. Wilson JN, Nokes DJ, Medley GF, et al. Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules. Vaccine 2007 25 : 3705 3712.
24. Sung JJ, Lik-Yuen H. HBV-ISS (Dynavax). Curr Opin Mol Ther 2006 8 : 150 155.
25. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP); Part I: immunization of infants, children, and adolescents. MMWR 2005 54 : RR-16.
26. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP); Part II: immunization of adults. MMWR 2006 55 : RR-16.
27. Simard EP, Miller JT, George PA, et al. Hepatitis B vaccination coverage levels among healthcare workers in the United States, 2002-2003. Infect Control Hosp Epidemiol 2007 28 : 783 790.
28. Chen H, Cantrell CR. Prevalence and factors associated with self-reported vaccination rates among US adults at high-risk of vaccine-preventable hepatitis. Curr Med Red Opin 2006 22 : 2489 2496.
29. Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis 2005 37 : 622 627.
30. CDC. Progress in hepatitis B prevention through universal infant vaccination - China, 1997-2006. MMWR 2007 56 : 441 445.
31. Hislop TG, The C, Low A, et al. Hepatitis B knowledge, testing and vaccination levels in Chinese immigrants to British Columbia, Canada. Can J Public Health 2007 98 : 125 129.
32. Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007 132 : 1287 1293.
33. Van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003 10 : 294 297.
34. Park SD, Markowitz J, Pettei M, et al. Failure to respond to hepatitis B vaccine in children with celiac disease. J Pediatr Gastroenterol Nutr 2007 44 : 431 435.
35. Samandari T, Fiore AE, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007 120 : e373 e381.
36. Mele A, Mariano A, Tosti ME, et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis 2007 44 : e17 24.
37. Shiau YT, Huang YH, Wu JC, et al. Analysis of humoral immunity of hepatitis D virus DNA vaccine generated in mice by using different dosage, gene gun immunization, and in vivo electroporation. J Chin Med Assoc 2006 69 : 7 13.
38. Wang SY, Wu JC, Chiang TY, et al. Positive selection of hepatitis delta antigen in chronic hepatitis D patients. J Virol 2007 81 : 4438 4444.
39. Tanaka Y, Hanada K, Mizokami M, et al. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002 99 : 15584 15589.
40. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006 144 : 705 714.
41. Encke J, Findeklee J, Geib J, et al. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol 2005 142 : 362 369.
42. Li W, Li J, Tyrell DL, Agrawal B. Expression of hepatitis C virus-derived core or NS3 antigens in human dendritic cells leads to induction of proinflammatory cytokines and normal T-cell stimulation capabilities. J Gen Virol 2006 87 : 61 72.
43. Elmowalid GA, Qiao M, Jeong SH, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007 104 : 8427 8432.
44. Torresi J, Stock OM, Fischer AE, et al. A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology 2007 45 : 911 92044.
45. Encke J, Radunz W, Eisenbach C, et al. Development of a heterologous, multigenotype vaccine against hepatitis C virus. Eur J Clin Invest 2007 37 : 396 406.
46. Di Bisceglie AM, Frey S, Gorse GJ, et al. A phase I safety and immunogenicity trial of a novel E1E2/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults. (Abstract). Hepatology 2005 42 (Suppl 1 750A.